Boston Scientific price target raised to $100 from $90 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific to $100 from $90 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results for the MedTech sector. While the firm believes that any hurricane related headwind call-outs for Q4 will generally get “a pass” from investors, it could cause companies with elective or deferrable procedure areas to see more muted guide increases, the analyst tells investors in a research note. For the stock, Truist contends that a higher multiple is warranted based on incremental growth catalysts that could come into focus into year end, including Option readout for Watchman, and possible earlier than expected data read/submission for Acurate.